Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DDP 225

Drug Profile

DDP 225

Latest Information Update: 29 Dec 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Dynogen Pharmaceuticals
  • Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Major depressive disorder; Nausea and vomiting; Overactive bladder

Most Recent Events

  • 23 May 2008 Adverse events data from a Phase-IIa trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
  • 17 Jan 2008 Patent rights and know-how relating to DDP 225 transferred from Arachnova Therapeutics to Dynogen Pharmaceuticals through an asset purchase agreement
  • 20 Dec 2007 Discontinued - Phase-II for Nausea and vomiting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top